Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine-releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in-development treatments for peak-dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. ANN NEUROL 2018;84:797-811 D yskinesia, often referred to as L-dopa-induced dyskinesia (LID) to recognize L-dopa as the major contributor, is a motor complication arising in patients with Parkinson disease (PD) on chronic L-dopa treatment, largely in a dose-dependent fashion-except when given as an infusion, such as in L-dopa/carbidopa intestinal gel. 1 LID is phenomenologically recognized as chorea/choreoathetoid movements appearing initially on the more affected body side. LID occurs in 40% of patients after 4 years on L-dopa treatment, with risk especially high in younger patients treated with higher doses of L-dopa.
variable topographical distribution and to be reported as more troublesome compared with peak-dose dyskinesia. When exclusively affecting the legs, ballistic or stereotypic alternating movements may predominate (Fig 2, Supplementary Video 4). 5 Some of these movements may give rise to bizarre but highly stereotypical gait patterns. 6 It is distinct from but can evolve into wearing-off dystonia, typically expressed as toe curling, sometimes with plantar flexion or inversion. 7 A similar common low-dose phenomenon is early morning dystonia (Supplementary Video 5).
Dyskinesia and L-dopa L-dopa is necessary but insufficient to generate LID. LID requires a pulsatile delivery (short half-life), a presynaptic nigrostriatal degeneration, and a relatively preserved postsynaptic nigrostriatal system. In most atypical parkinsonisms, such as progressive supranuclear palsy, where the postsynaptic system is affected, L-dopa rarely induces dyskinesia. Although there is a dose-dependent increase in FIGURE 1: Time course of diphasic dyskinesia according to 3 different theoretical plasma L-dopa concentrations. This diagram illustrates the 4 theoretical pharmacokinetic states of a single dose of L-dopa as it increases (y-axis) over a 4-hour approximate time horizon between L-dopa doses (x-axis; although shown of similar magnitude, the width of each state is variable within and between patients). The therapeutic window (ON state, optimal clinical benefits) becomes virtual with disease progression, encroached by the sub-and supratherapeutic windows. The subtherapeutic window is divided into the OFF (loss of clinical benefits with reemergence of parkinsonian features) and "transitional" states. The latter may result in periods of diphasic dyskinesia (A, at both ends of the L-dopa dose cycle) or longer, more disabling diphasic dyskinesia states (C) that could be mistaken for peak-dose square wave response (A, during the peak concentration). Pharmacotherapeutic strategies will differ in each scenario. L-dopa dose should be reduced (or amantadine considered) in A but increased in C; L-dopa dose interval may be shortened in B. An acute apomorphine or L-dopa challenge can resolve uncertainty, as it reduces or eliminates diphasic dyskinesia but leaves unchanged or worsens peak-dose dyskinesia. Adapted from Verhagen Metman and Espay.
100 DiDysk = diphasic dyskinesia; LD = L-dopa.
peak-dose dyskinesia when L-dopa is administered orally, 8 such effect is lost when it is delivered continuously. Continuous L-dopa infusion typically reduces pre-existent LID, even with a dose higher than that used orally. 1 This may be due to favorable pharmacodynamic effects of continuous L-dopa delivery despite a higher area under the curve and a more physiologic (tonic) stimulation of dopamine receptors. Although L-dopa is necessary for dyskinesia development, the clock for this complication begins to tick at disease onset rather than upon L-dopa initiation. Long-term studies have consistently shown that motor complications develop with the same frequency and severity irrespective of whether L-dopa was initiated early or late. 9 This was best demonstrated by a study on L-dopa initiation in subSaharan African PD patients, whose longer delay in receiving L-dopa (mean = 4.2 years) than matched patients in Italy (1.8 years) 10 was associated with a shorter dyskinesiafree period. The exact same finding has repeatedly been reported in preclinical settings using both rodent and primate models of parkinsonism and dyskinesia, with most animals being capable of displaying dyskinesia at first L-dopa exposure if the lag time between lesion establishment and pharmacological challenge is long enough. 11 Such data have led to a modification of the concept of priming, proposing that it is the direct and intrinsic consequence of the loss of dopamine innervation of the striatum, with the first injections of dopaminergic drugs sensitizing but not inducing it. 11 The evidence collectively suggests that disease severity and L-dopa dose are more important than duration of Ldopa treatment for the development of dyskinesia in PD. 12 Furthermore, young age at onset, low body weight, female sex, and more severe motor disability may represent important vulnerabilities and highlight an important contribution of L-dopa dose in these high-risk groups. 13 Although greater risk for LID may be accrued in certain clinical subtypes (eg, akinetic-rigid compared to tremor-dominant 14 ) and genetic polymorphisms (eg, the Val158Met variant of COMT 15 ), these associations remain tentative and at present have little clinical application. Nevertheless, the bizarre but highly stereotypical gait associated with diphasic dyskinesia in young onset PD patients may be more common in patients with PRKN (PARKIN, PARK2) mutations. 16 Of note, diphasic dyskinesia has been found to be associated with the DRD3 p.S9G variant, with the AA genotype shortening its time to onset after L-dopa initiation. 17 
Dyskinesia and Disability
With therapeutic doses of L-dopa, hypokinetic disability might be replaced with dyskinetic disability. As hypokinesia is generally more bothersome, patients usually prefer the dyskinetic to the parkinsonian state. 18 Although an undesirable outcome, dyskinesia is also generally a marker of treatment success, indicating the point at which dopaminergic replacement has reached and surpassed the therapeutic window. PD patients who have never exhibited dyskinesia may be undertreated with potentially greater net disability, because the onset and offset of therapeutic and dyskinetic thresholds have been demonstrated to be similar. 12 Advanced L-dopa-treated PD patients, thus, may alternate between tremor, gait freezing, or other parkinsonian features and LID (peak-dose and/or diphasic), with no "sweet spot" in between.
The highest tolerable doses of the dopamine agonists (pramipexole, ropinirole, rotigotine) exhibit lower efficacy than L-dopa and may induce or worsen dyskinesia once patients begin concurrent oral L-dopa treatment. Therefore, rather than delaying dyskinesia, as proposed in the CALM-PD 19 and REAL-PET 20 studies, dopamine agonists are mostly incapable of extending their effect into and beyond the therapeutic window, defined by a period of optimal response to L-dopa, to generate dyskinesia when given without L-dopa. Importantly, the CALM-PD and REAL-PET studies, comparing pramipexole and ropinirole, respectively, to L-dopa as early monotherapies, showed superior motor improvement and quality of life in the L-dopa-treated groups. These endpoints were deemphasized, whereas the greater incidence of dyskinesia in the L-dopa-treated arm was emphasized, ushering in "Ldopa-sparing" by means of early initiation of dopamine agonists to avoid or postpone LID. Separately, the PD MED trial (long-term comparison of L-dopa, dopamine agonists, and monoamine oxidase B inhibitors as first-line treatment in 1,620 PD patients, with mean age = 70 years, recruited over 9 years and followed for a median of 3 years) also showed that dopamine agonists provided less overall benefit than L-dopa despite the the L-dopa group having significantly more dyskinesia. 21 
Pathophysiology
The current model of LID pathophysiology, mainly focused on peak-dose dyskinesia, hypothesizes the following events at the striatal level: pulsatile stimulation of dopamine receptors, excessive presynaptic swing of dopamine leading to increased receptor occupancy, 22 dissociation between low intrastriatal dopamine and high plasma and extracellular L-dopa, 23 downstream changes in the postsynaptic compartment, and abnormalities in nondopaminergic neurotransmitters. All of these events cause changes in the firing patterns and the oscillatory activity between the basal ganglia and the motor cortex, leading to excessive disinhibition of thalamocortical neurons and overactivation of the motor cortex. Understanding these mechanisms of LID at network and synaptic levels can assist in the development of neuromodulatory or pharmacological interventions.
Network Mechanisms
The mechanism of LID at the network level has been studied in PD patients using a variety of neurophysiological and neuroimaging methods, including local field potentials (LFP), transcranial magnetic stimulation (TMS), 24 voxel-based morphometry, and functional magnetic resonance imaging. 25, 26 Classically, an excessive reduction of the firing rate in the globus pallidus pars interna (GPi) and in the subthalamic nucleus (STN) secondary to nonphysiological stimulation of dopamine receptors in the denervated striatum has been associated with LID. 27 Registration of LFP in animals and humans suggests that alterations in firing patterns, including changes in synchronization, may be more relevant than changes in firing rates. Animal studies show a strong coherence between the basal ganglia and frontal cortical activity during LID. Limited data from human subjects have examined the coherence between cortical and subcortical structures in patients treated with deep brain stimulation (DBS). Unlike the hypersynchronous activity in the beta band (20-30Hz) associated with the akinetic or "OFF" medication state, the hyperkinetic LID state is characterized by a reduction of power in the beta-band LFP activity, 28 hypersynchronous gamma oscillations between 60 and 90Hz in the motor cortex and STN, and strong phase coherence between them, with no or minimal influence of voluntary movements. 29 A novel adaptive (closed-loop) DBS device reduced LID by decreasing the voltage of stimulation when detecting a decrease in betaband activity in the STN. 30 An inconsistency of the classical firing-rate model in predicting LID is that it does not consider the strong connections between the basal ganglia and the motor cortices. Abnormal synaptic plasticity has been demonstrated by TMS studies to arise from the primary motor cortex (M1). 24, 31 Beyond M1, functional and structural abnormalities have also been demonstrated by structural and functional neuroimaging in motor areas involved in motor planning and inhibition, such as the supplementary motor area and inferior frontal cortex (Table 1 , Fig 3) .
Molecular and Synaptic Mechanisms
LID-generating mechanisms at the synaptic level show biochemical abnormalities associated with LID in dopaminergic 22 and nondopaminergic receptors 32 and in striatal enzymes regulating dopaminergic signaling (see Fig 3) . 33 In this regard, alterations of the serotonergic system, 34 phosphodiesterase 10A, 33 and the glutamatergic system 35 support a pathogenic role of N-methyl-D-aspartate (NMDA) receptors in LID development (Fig 4) .
Role of Dopamine. Dopamine receptors occupy a prominent role in the pathophysiology of LID, even if any relationship between the two is affected by factors such as age and genetic background. 36 D1 receptor activation is a key factor for the development of LID. Although a preferential selectivity by oral dopamine agonists for D2-D3 receptor subtypes with no affinity for D1 and D5 receptors 37 could explain their lower prodyskinetic effects, activation of striatal D3Rs exerts a synergistic effect on D1R-mediated transmission through direct intramembrane interaction. 38 Thus, the binding of pramipexole to D3R boosts D1R function, which explains both its antiparkinsonian efficacy and its prodyskinetic effects. Rotigotine has also been shown to be a potent agonist at D1 receptors. 39 LID is associated with several molecular changes at the striatal level likely mediated by overactivation of dopamine D1 receptors such as increased FosB and prodynorphin messenger RNA expression 40 and the initiation of 2 processes down-stream that are likely linked to extracellular signal-regulated kinase (ERK) signaling pathways: an abnormal activation of mitogen-and stress-activated kinase 1 (MSK1) and a phosphorylation of histone H3.
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D1/DARPP32 activation by L-dopa induces phospho-ERK translocation in the nucleus and the consequent activation of MSK1, which has a key role in the regulation of synaptic plasticity and transcriptional activity. 42 Abnormal regulation of MSK1 facilitates the induction of LID and increase in striatal ΔFosB, possibly mediated by increased histone H3 phosphorylation at the FosB promoter. 43 The possible differential role of direct-and indirect-pathway spiny neurons in LID has been recently shown in a study using a new chemogenetic technology 44 ; stimulation of Gq-coupled human M3 muscarinic receptors in directpathway spiny neurons caused a beneficial antiparkinsonian effect in mice and a surge of LID, whereas indirect pathway activation did not.
LID is associated with corticostriatal plastic alterations at the synaptic level, shown by a reversal of long-term potentiation (LTP) or loss of "synaptic depotentiation." 45 The loss of this homeostatic synaptic mechanism was found to be associated with increased activity of the molecular cascade downstream of the D1 dopamine receptors leading to an increase in DARPP32 phosphorylation. 45 A spike-timing-dependent protocol has revealed that the homeostatic adaptation in intrinsic excitability of spiny neurons is lost in mice with LID, suggesting an alteration of the number of corticostriatal synapses 46 and a switch from bidirectional to unidirectional striatal plasticity. 47 An M4 muscarinic receptor allosteric modulator enabled LTP reversal and reduced dyskinetic behaviors in a primate model, suggesting muscarinic receptors as potential targets for pharmacotherapy against LID. 48 In line with these observations, a reduced bidirectional plasticity has also been observed in dyskinetic PD patients in the substantia nigra pars reticulata by LFP recording with DBS electrodes 49 and in the cerebral motor cortex using TMS. LID can also be associated with abnormal structural synaptic plasticity. Both D1-and D2-receptor-positive spiny neurons have diminished spine density in the rodent-denervated striatum.
51 Surprisingly, however, longterm L-dopa treatment causing dyskinesia restores spine density in D2-but not in D1-receptor-positive spiny neurons, suggesting that these morphological changes might represent structural underpinnings of LID in PD.
Role of Glutamate. Hyperactivity of corticostriatal glutamatergic transmission has been shown in animal models of PD and postulated in PD patients with LID, possibly resulting from receptor and molecular alterations at preand postsynaptic levels due to dopaminergic loss. 52 Dyskinetic rats have high striatal levels of the NMDA receptor GluN2A subunit but low levels of the GluN2B subunit in the postsynaptic compartment, suggesting a pathological redistribution of receptors between synaptic and extrasynaptic glutamatergic membranes in LID. 53 An altered ratio of synaptic striatal GluN2A/GluN2B-containing NMDA receptors has also been found in dyskinetic monkeys and in postmortem tissue from dyskinetic PD patients. A cell-permeable peptide interfering with the GluN2A subunit interaction with protein postsynaptic density protein 95 reduced dyskinesia in LID models. 54 Recent studies identified a possible molecular partner in LID modulation through GluN2A subunits. 55 The interaction between the synaptic protein rabphilin 3A and GluN2A-containing NMDA receptors is increased in parkinsonian rats developing dyskinesia. A cell-permeable peptide interfering with this interaction decreases LID.
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Role of the Serotonergic System. In the face of striatal dopamine denervation, L-dopa conversion to dopamine migrates to nondopaminergic cells, particularly serotonergic raphe nuclei neurons. 56 Dopamine is then released by serotonergic neurons in a nonphysiological, unregulated manner in the extrasynaptic cleft, where it might act as a "false transmitter," causing abnormal and pulsatile activation of striatal dopamine receptors. 57 Reducing abnormal dopamine release via presynaptic serotonergic 5-HT1A agonists can decrease dyskinesia in parkinsonian models. 58 Moreover, ablation of serotonergic transmission reduced LID, 59 whereas transplants of serotonin-enriched grafts worsened LID in parkinsonian rats. 60 Role of Other Nondopaminergic Mechanisms. Within the basal ganglia, chronic pulsatile dopamine receptor stimulation leads to alterations in cholinergic, opioid, histaminic, adrenergic, and cannabinoid function. Acetylcholine is integral to striatal function. Cholinergic interneurons are modulated by dopamine, and striatal dopamine release is regulated via a disynaptic pathway involving cortical and thalamic glutamatergic inputs to the cholinergic interneurons with stimulation of nicotinic acetylcholine receptors on nigrostriatal axons. 61 Agonists at subtypes of nicotinic receptors have been shown to reduce LID. 62 The mechanism may involve reducing dopamine release via a chronic desensitization or downregulation of nicotinic receptors. 63 Muscarinic cholinergic receptor involvement in LID is less clear, with cholinergic antagonists at M4 receptors possibly reducing dystonia but exacerbating chorea. Histamine H 2 receptors located within the striatum may reduce LID via modulation of acetylcholine. 64 The opioid peptide precursors, proenkephalin and prodynorphin, are cotransmitters in the γ-aminobutyric acidergic striatopallidal pathways and function as neuromodulators. Many studies have shown increased levels of prodynorphin breakdown products linked to the expression of LID in animal models of PD. 65 Mu-subtype opioid receptors appear to modulate activity of the direct striatopallidal pathway, and antagonists at this receptor Within the striatum, dopaminergic terminals (red terminal) release dopamine (DA), and D2 autoreceptors and uptake processes also control synaptic DA levels. DA binds striatal postsynaptic D1 receptors, inducing the formation of cyclic adenosine monophosphate (cAMP) via adenylyl cyclase (AC), which in turn favors the activation (black arrows) of protein kinase A (PKA), which is able to phosphorylate and activate DA-and cAMP-regulated phosphoprotein of 32 kDa and extracellular signal-regulated kinase (ERK). Activated phospho-ERK (pERK) induces an abnormal activation of mitogen-and stress-activated kinase 1 (MSK1) and the final phosphorylation of histone H3 (P-H3). Phosphorylated DA-and cAMP-regulated phosphoprotein 32 kDa (P-DARPP32) inhibits (dotted line) protein phosphatase 1 (PP1). Glutamate (Glu) is released from corticostriatal terminals (light blue terminal) into the striatum and activates N-methyl-D-aspartate receptors, whose activity increases intracellular levels of calcium (Ca
2+
). Increased intracellular Ca 2+ levels facilitate the production and release of endocannabinoids eCBs, which in turn act on CB1 receptors at presynaptic terminals, limiting Glu release. Presynaptic modulation of Glu and DA release are also achieved by the activation of opioid receptors. The serotonergic afferents (green terminal) release serotonin into the striatum, which is regulated by 5-HT1 autoreceptors. These afferents take up L-dopa, convert it to DA, and then release DA in an unregulated fashion. Finally, cholinergic acetylcholine interneurons (yellow terminal), by overstimulation of nicotinic acetylcholine receptors (nACh) on dopaminergic terminals, contribute to the abnormal DA release (see text for details and information on other mechanisms). 5-HT = serotonin; 5-HT1 = 5-hydroxytryptamine receptor 1; ACh = acetylcholine; ATP = adenosine triphosphate; CB1 = cannabinoid receptor type 1; D1 = dopamine D1 receptor; D2 = dopamine D2 receptor; ER = endoplasmic reticulum; Gaba = γ-aminobutyric acid; GluN2A/2B = N-methyl-D-aspartate receptor subunits 2A and 2B ratio; PDE10A = phosphodiesterase 10A; SPN = spiny projection neuron. may reduce LID. 66 Opioid signaling is complex, however, and other authors have shown increased LID with some opioid antagonists. 67 The cannabinoid system is implicated in basal ganglia function, with endocannabinoids involved in glutamate/dopamine signaling and striatal plasticity. 68 Cannabinoid CB1 receptors are also highly expressed in the internal segment of the GPi, the output region of the basal ganglia. 69 The pharmacology is complex, with both CB1 agonists and antagonists reducing LID. 70 Targeting the enzymatic breakdown of cannabinoids using fatty acid amide hydrolase inhibitors may also reduce LID. 71 Noradrenergic signaling may also be involved in LID, although the mechanisms are unclear. Both alphaand beta-adrenergic receptor antagonists can reduce LID in animal models. 72 
Management
Available Oral Pharmacological Treatments Diphasic LID is managed in a manner similar to wearingoff symptoms: increasing the individual L-dopa doses, converting to a long-acting formulation of L-dopa, or adding longer-acting dopaminergic medications (eg, a monoamine oxidase B inhibitor, catechol-O-methyltransferase inhibitor, or dopamine agonist). No clinical trials focused on diphasic dyskinesia have been reported. Anecdotally, apomorphine was observed to reduce the duration of diphasic dyskinesia at doses higher than necessary to induce an ON phase. 73 Below, we summarize the available strategies assessed for direct effect against peak-dose LID for which sufficient evidence exists. We do not include drugs for which any antidyskinetic effect has been assumed indirectly, emerging from the "ON time without troublesome dyskinesia" endpoint used in clinical trials (eg, safinamide) or because of a reduction in dopaminergic tone in L-dopa-sparing interventions (eg, dopamine agonists).
Amantadine. An NMDA antagonist, amantadine is the most widely used oral therapy for dyskinesia. The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee classified amantadine as "efficacious" in the treatment of dyskinesia. 74 The safety of amantadine is considered acceptable, although side effects such as confusion, hallucinations, ankle edema, constipation, and dry mouth narrow the therapeutic window. ADS-5102 (amantadine extended release) was recently approved by the US Food and Drug Administration (FDA) "for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications." 75 Compared with placebo, ADS-5102 274 mg significantly reduced dyskinesia as measured by the Unified Dyskinesia Rating Scale (treatment difference = −7.9, p < 0.001). 75 Additional studies will be needed to investigate the comparative efficacy between ADS-5102 and immediate-release amantadine.
Clozapine. Off-label targeting of 5HT 2A/2C receptors by this atypical antipsychotic has shown anti-LID efficacy in a single randomized controlled trial, without worsening PD motor symptoms, and has also been considered "efficacious." 76 Another proposed mechanism for its antidyskinetic action in low doses is D1 receptor antagonism. 77 However, clinical usefulness is limited due to safety issues. 74 Levetiracetam. Off-label levetiracetam has yielded conflicting antidyskinetic efficacy and tolerability. 78 The purported anti-LID mechanism of action includes a change in the expression of certain transcription factors in the striatum.
Pharmacological Treatments in Clinical Development
Several drugs with a variety of potentially relevant mechanisms of action, targeting receptors/neurotransmitters within the basal ganglia, are at various stages of clinical development ( Table 2) . Selection of potential symptomatic therapies for the management of PD has benefited from studies on the methylphenyltetrahydropyridine-treated macaque monkey, an excellent phenocopy of the motor symptoms and side effects of dopaminergic therapies. 79 This model has been widely used in the preclinical evaluation of the various experimental therapeutics. 79 Targets under evaluation exclusively in preclinical models are beyond the scope of this review.
Serotonergic Targets. Although mixed agonists for both 5-HT1A and 5-HT1B receptors prevent the expression of LID, they may also reduce the therapeutic effect of L-dopa. 80 Despite reducing dyskinesia, the 5-HT1A agonist sarizotan failed in phase III studies partly due to worsening of motor symptoms. 81 Phase IIb studies of the clinically available 5-HT1A agonists, buspirone 82 and eltoprazine, 83 are ongoing (ClinicalTrials.gov NCT02617017 and NCT02439125, respectively). The advantage of both of these agents is their rapid clinical availability if efficacy and tolerability are demonstrated in these studies. The added potential to reduce anxiety with such 5-HT1A agonists represents an additional benefit to PD subjects.
Novel Glutamate Targets. Tolerability of glutamatergic agents has been a major issue to date, with off-target side effects including confusion, hallucinations, and ataxia. As noted above, the longer-acting preparation of the NMDA antagonist, amantadine ADS-5102, was recently approved by the FDA. A second long-acting amantadine HCL extended release was also recently approved, but no details of clinical studies have been reported to date. Their potential advantage is theoretically less night-time confusion/ hallucinations, but this has not been examined in direct comparison with standard amantadine. Recent studies of allosteric modulators of NMDA receptors have also been suggested to be better tolerated due to more selective basal ganglia targeting and wider therapeutic index. 84 Abnormal corticostriatal plasticity could theoretically be restored in part by the use of metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators, which reduce LID in rodent and primate models. 85, 86 Early clinical studies of several mGluR5 antagonists showed some shortterm antidyskinetic benefits, but side effects of worsened PD motor symptoms has limited further development. 87 Many other targets have been previously investigated in phase II/III clinical trials, but these either have failed to reduce LID to a significant or clinically meaningful level compared to placebo or have been poorly tolerated. Several challenges exist in the translational field for novel drugs to reduce LID, ranging from animal models to clinical trial designs to the availability of clinically safe agents required to evaluate the target of interest. Future strategies in the field thus need to address these issues with improved translational methodology (including animal models, dyskinesia rating scales, and factors related to the heterogeneity of PD) as well as technology to aid in the measurement of LID and the use of artificial intelligence to increase the scope of potential targets to evaluate. 88 Advanced Therapies (Requiring Invasive Interventions) Due to the paucity of optimal oral pharmacological treatments for LID, 3 advanced treatment strategies have been developed: DBS, infusion of LCIG, and continuous subcutaneous apomorphine infusion (CSAI).
Deep Brain Stimulation. DBS is an invasive neurosurgical technique that delivers continuous electrical stimulation in specific brain areas by means of electrodes connected to an implantable pulse generator placed in the upper chest. Two main targets are used to treat LID in PD: the STN and the GPi. 89 STN DBS has a profound ameliorative effect on LID due to at least 3 mechanisms: (1) reduction of medications by 50 to 60%, as consistently seen by many prospective studies 90 ; (2) stimulation of pallidothalamic fibers in the zona incerta; and (3) plastic changes of the basal ganglia circuits that modulate L-dopa responsiveness. A longstanding debate on the perceived superiority of STN over GPi inspired the execution of randomized prospective studies. The meta-analysis of 3-year results of these comparative studies concluded that the 2 targets are comparable in the short term, but GPi is significantly better than STN in reducing LID. 91 This finding confirms that GPi-DBS has a direct and profound antidyskinetic effect, regardless of any postsurgical modification in the dosage of dopaminergic therapies.
Infusion of LCIG. LCIG allows the continuous infusion and reliable absorption of L-dopa in the jejunal lumen, leading to sustained plasma levels. The system requires the endoscopic placement of a gastrostomy tube with an inner jejunal extension, connected to a pump that holds replaceable cassettes of 2g of L-dopa. Retrospective studies and recent prospective trials have confirmed a significant reduction in LID. 92 A post hoc analysis of the 1-year data from LCIG pivotal studies in the subgroup of patients defined by ≥1 hour of ON time with troublesome dyskinesia demonstrated a reduction compared to baseline within this small cohort (n = 144) despite higher total daily L-dopa doses, suggesting a beneficial pharmacodynamic effect. 1 Some LCIG patients may develop disabling diphasic LID in the morning and at the end of the day, when L-dopa levels rise and wear off, respectively.
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Diphasic LID may be misinterpreted as peak-dose in some LCIG-treated PD patients (see Supplementary Video 3); their proper management requires increasing the dose of LCIG or adding other dopaminergic medications. 93 Continuous Subcutaneous Apomorphine Infusion. Apomorphine is the only dopamine agonist administered subcutaneously, with the strongest D1 and D2 receptor affinity and shortest half-life. A meta-analysis of 390 patients from 21 uncontrolled open-label studies over a mean time frame of 24.8 months (range = 6-57 months) reported a mean LID reduction of 36%. 94 The improvement in LID severity depends in part on the extent to which oral dopaminergic medications with short half-life, such as L-dopa, can be replaced by CSAI. In some cases, this may require doses that are not tolerated, especially by elderly patients (eg, confusion, psychosis, worsening of coexisting dysautonomia). Also, a common long-term complication of infusion is the occurrence of subcutaneous nodules. As a result, many centers in Europe use CSAI as a bridge treatment for fluctuating patients waiting to receive LCIG or DBS. 95 This treatment modality is under evaluation in the USA. To date, no randomized studies comparing the aforementioned 3 strategies have been performed. A study comparing STN DBS and LCIG reported an overall similar short-term effect on motor fluctuations, although STN DBS may have been more effective against LID and associated with fewer adverse events. 96 A pharmacological study comparing the acute and chronic effects of L-dopa in a relatively small group of patients receiving either STN DBS, LCIG, or CSAI concluded that DBS was the best strategy for LID reduction. 97 
Conclusions and Future Directions
LID is one of the most studied but also least optimally managed treatment complications in PD. A limitation of clinical research rests in the difficulty in categorizing dyskinesia as peak-dose versus diphasic, given the phenomenological overlap. This has resulted in combining patients with different dyskinesia types and presumably different pathophysiologic mechanisms in clinical studies. Further work is needed to develop consensus guidelines for translating candidate therapies from clinical trials, proper LID models to guide drug development, and L-dopa dosing and formulations to extend half-life. In addition, one important challenge to the establishment of effective antidyskinetic therapies is the high placebo effect demonstrated in a number of studies. 98 Rigorous, placebocontrolled trials will be important to better define the true treatment effect of any future intervention. The current state of therapy for LID is promising, with numerous pharmacologic and nonpharmacologic treatment options. Besides the newly approved extendedrelease oral formulation of amantadine, a range of molecular and neuromodulative therapies are under evaluation in the therapeutic pipeline. It is conceivable that future improvements in L-dopa delivery alone, through longacting L-dopa preparations or infusion systems, 99 may prevent the pharmacodynamic alterations associated with short-acting oral L-dopa, and thus lower the prevalence of LID if initiated early.
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